Cognitive Decline & Alzheimer's Risk
Family history of dementia, noticeable memory change, or you want the earliest possible read on brain health while there's still time to act.
- Tests9
- With code$608.36
Order it in one cart
One draw at a Quest lab near you, no doctor’s visit. The prices are Marek’s own, with code CAMERON applied.
$608.36$675.95with code CAMERON
Drawn at any Quest location in the US, no doctor’s visit (not NY, NJ or RI). Marek’s checkout adds its one-time blood-draw fee to individual tests and shows the total before you pay.
What is in it
9 tests: $675.95 before the code, $608.36 with code CAMERON. Every marker links to its own free page.

The free Before‑You‑Stack Lab Kit
The 12 labs I’d run before any protocol, what each one tells you, add-ons by goal and how to order them yourself. The PDF is yours straight away.
After that it is about two emails a week: a marker, a compound or a protocol. Unsubscribe in one click.
Before you order
Why these markers
Who it is for, what it answers, what most people miss
- Who it is for
Family history of dementia, noticeable memory change, or you want the earliest possible read on brain health while there's still time to act.
- What it answers
Alzheimer's pathology begins roughly two decades before symptoms. Blood-based markers that were research-only a few years ago can now detect it — and several contributors to cognitive decline are entirely reversible.
- What most people miss
Test the reversible causes before the irreversible one. B12 deficiency, hypothyroidism and severe sleep apnea all produce memory complaints that fully resolve when treated, and they are far more common than early Alzheimer's — this panel covers them first for that reason. On the newer marker: pTau-217 is the standout blood test of the last few years for Alzheimer's pathology, performing remarkably well against amyloid PET and spinal fluid, and it is genuinely a different category of test from anything else here. Understand what a positive means before you order it: it indicates pathology, not a diagnosis, and this is a result worth receiving alongside a clinician rather than alone in your inbox.
How to prepare, and what skews it
35 things can skew it
When and how to get it drawn
Fast 9–12 hours, morning. Off B12 supplements 1 week if you want a true B12 reading.
What skews the result
Some of these change your real level; others only change the reading. Each one says what to do.
- MetforminPhysiological state
Impairs B12 absorption over time; a well-documented effect from the DPPOS trial.
Do this: Test B12 (and MMA if borderline) at least annually on metformin.
Affects: Vitamin B12, Homocysteine- Kidney function and BMIPhysiological state
Both affect plasma concentrations of the tau and amyloid markers independently of brain pathology — a real limitation of blood-based neurodegeneration testing.
Do this: Interpret with kidney function in mind, and with a clinician.
Affects: pTau-217 (AD-Detect)- Sample handlingSample prep
These assays are sensitive to tube type, processing delay and freeze-thaw.
Do this: Use a lab that runs the validated workflow. Do not compare across platforms.
Affects: pTau-217 (AD-Detect)- Nothing physiological affects this resultAssay
Your genotype is fixed. No fasting state, time of day, illness, supplement or medication changes it, and a repeat test returns the same answer. Worth stating plainly rather than leaving blank.
Do this: Test once. Never repeat it.
Affects: APOE Genotyping- Risk is not destiny — and the quoted number is often misusedAssay
APOE e4 raises lifetime Alzheimer's risk, substantially with two copies. But many e4 carriers never develop dementia, and most people with Alzheimer's are not e4 homozygotes. Population risk figures get repeated as personal probabilities, which they are not.
Do this: Interpret with a clinician. The modifiable risk factors matter more than the genotype does.
Affects: APOE Genotyping- Consequences beyond the result itselfSample prep
In some countries a genetic result can affect life, disability or long-term care insurance underwriting, and protections vary. It also carries information about blood relatives who did not consent to learn it.
Do this: Decide whether you want to know before the blood is drawn. This is the rare result that cannot be un-seen.
Affects: APOE Genotyping- Serum B12 is a poor testAssay
It measures total B12, most of which is bound to haptocorrin and unavailable to cells. You can be tissue-deficient with a normal serum B12 — which is exactly why MMA exists.
Do this: A low-normal B12 with symptoms should be confirmed with MMA, not dismissed.
Affects: Vitamin B12- Recent B12 supplements or injectionsDrug or supplement
Raise serum B12 for weeks to months while tissue status may still be poor.
Do this: Testing after supplementing tells you little. Test before, or use MMA.
Affects: Vitamin B12- High-dose biotin, and intrinsic factor antibodiesAssay
Biotin interferes with the assay; intrinsic factor antibodies can cause falsely normal or high results in exactly the people with pernicious anemia.
Do this: Stop biotin 72 hours before. MMA cuts through both problems.
Affects: Vitamin B12- PPIs / acid reducersPhysiological state
Reduce stomach acid needed to absorb these nutrients.
Do this: Test B12, magnesium (RBC) and ferritin if on long-term acid suppression.
Affects: Vitamin B12- A B12 injection or high-dose supplementTiming
Supplementing before the draw normalizes MMA quickly and hides the deficiency you were testing for. This is the most common way a real B12 problem gets missed — the test is run after treatment has already started.
Do this: Draw MMA BEFORE starting B12, not after. Once supplemented, the window has closed for months.
Affects: Methylmalonic Acid (MMA)- Reduced kidney functionPhysiological state
MMA is cleared renally, so impaired kidney function raises it independently of B12 status. That turns the test that was supposed to resolve an ambiguous B12 into a second ambiguous number.
Do this: Read MMA alongside creatinine or cystatin C. With reduced clearance, homocysteine becomes the more informative functional marker.
Affects: Methylmalonic Acid (MMA)- Kidney impairmentPhysiological state
Raises MMA independently of B12 status, which is the main cause of a false-positive result.
Do this: Interpret against eGFR — a raised MMA in kidney disease is much weaker evidence of B12 deficiency.
Affects: Methylmalonic Acid (MMA)- Small intestinal bacterial overgrowthPhysiological state
Gut bacteria produce propionate, which raises MMA without B12 deficiency.
Do this: Consider SIBO if MMA is raised and B12 repletion doesn't lower it.
Affects: Methylmalonic Acid (MMA)- Delay before separating the sample — the big oneSample prep
Red cells keep producing homocysteine after the draw. If the sample isn't separated within about an hour, homocysteine rises measurably in the tube. This is the most common cause of a mildly raised result.
Do this: Ask for prompt separation or a chilled sample. Repeat an isolated high value at a lab that handles it properly.
Affects: Homocysteine- B12, folate and B6 statusPhysiological state
Homocysteine rises when any of the three is low — which is what makes it a useful functional marker rather than an independent finding.
Do this: A raised homocysteine is a prompt to check B12 and folate.
Affects: Homocysteine- Kidney functionPhysiological state
Impaired renal clearance raises homocysteine independently of B12, folate or B6 status.
Do this: Read against eGFR before concluding a raised homocysteine means a vitamin deficiency.
Affects: Homocysteine- Biotin (B7)Assay
Biotin interferes with the streptavidin-biotin immunoassays most hormone tests run on. Depending on the assay design it pushes the result falsely HIGH or falsely LOW — there is no single direction to correct for. Hair, skin and nail products are the usual source, and doses in those are far above the RDA.
Do this: Stop biotin 48–72 hours before the draw, and check every supplement label rather than just the one labeled biotin.
Affects: TSH (Thyroid-Stimulating Hormone)- Time of dayTiming
TSH is pulsatile and diurnal — it peaks overnight and falls through the morning. An 8am and a 2pm draw can differ by roughly a third, which is enough to move someone in or out of the reference range.
Do this: Draw early morning, and always at the same time when tracking.
Affects: TSH (Thyroid-Stimulating Hormone)- Levothyroxine timingDrug or supplement
Taking your dose before the draw measures the tablet, not your steady state. Separately, iron, calcium, magnesium and coffee all block absorption — a dose that 'stopped working' is usually one taken with breakfast.
Do this: Draw before your morning dose. Keep the tablet four hours from iron and calcium.
Affects: TSH (Thyroid-Stimulating Hormone)- Acute illnessPhysiological state
Non-thyroidal illness syndrome moves TSH in either direction during any significant illness, and it is not thyroid disease.
Do this: Do not diagnose a thyroid problem from a panel drawn while unwell.
Affects: TSH (Thyroid-Stimulating Hormone)- Season and sun exposureTiming
Levels swing substantially between late summer and late winter — the same person can differ by 20 ng/mL across the year.
Do this: Test at the same time of year when tracking, and know which end of the swing you measured.
Affects: Vitamin D (25-Hydroxy)- D2 vs D3, and assay variationAssay
Some assays measure only D3, others total. Between-lab variation in vitamin D testing is larger than most people assume.
Do this: Stay with one lab. Do not chase small differences.
Affects: Vitamin D (25-Hydroxy)- Recent high-dose supplementationDrug or supplement
A weekly or monthly bolus produces a peak that does not represent your steady state.
Do this: Test at least a week after a large dose.
Affects: Vitamin D (25-Hydroxy)- Anything that shortens red cell lifespanAssay
HbA1c measures glucose stuck to hemoglobin over the red cell's lifespan. Hemolysis, recent blood loss, recent transfusion or erythropoietin all shorten that lifespan and give the sugar less time to attach — producing a falsely LOW HbA1c in someone whose glucose control is actually poor.
Do this: If you are anemic, have donated blood recently, or are on TRT with a high hematocrit, read HbA1c alongside fasting glucose and fructosamine.
Affects: HbA1c (Hemoglobin A1c)- Iron deficiencyAssay
Raises HbA1c independently of glucose — older red cells accumulate more glycation. Correcting iron deficiency lowers HbA1c with no change in diet at all.
Do this: Check ferritin before acting on a borderline HbA1c.
Affects: HbA1c (Hemoglobin A1c)- Hemoglobin variantsAssay
Sickle trait, HbC and thalassemia interfere with several HbA1c methods, in either direction depending on the assay.
Do this: Relevant if you have African, Mediterranean, Middle Eastern or South Asian ancestry. Ask which method the lab uses.
Affects: HbA1c (Hemoglobin A1c)- CorticosteroidsPhysiological state
Raise glucose and white cells; suppress your own cortisol and ACTH production.
Do this: Note recent steroid use — including injections — when interpreting. Never stop long-term steroids abruptly.
Affects: HbA1c (Hemoglobin A1c)- Blood donation / phlebotomyPhysiological state
Lowers ferritin substantially; can falsely lower HbA1c by shortening red cell lifespan.
Do this: Track ferritin every time you donate — the classic TRT trap. Note recent donation when reading HbA1c.
Affects: HbA1c (Hemoglobin A1c)- Oral estrogen and hormonal contraceptivesDrug or supplement
They raise CRP through hepatic protein synthesis without any true increase in inflammation. This is the single most common reason a young healthy woman gets an alarming hs-CRP.
Do this: Note the contraceptive on the requisition and interpret hs-CRP against that, not against the standard risk bands.
Affects: hs-CRP (High-Sensitivity C-Reactive Protein)- Anything that inflamed you in the last two weeksTiming
hs-CRP is measuring the slow burn, but it cannot tell that apart from a cold, a dental infection, a vaccination or a brutal training session three days ago. Those push it into the high-risk band transiently and it reads identically.
Do this: If hs-CRP is high, repeat it two to four weeks later while well. One elevated reading is not a cardiovascular risk signal — a persistently elevated one is.
Affects: hs-CRP (High-Sensitivity C-Reactive Protein)- Acute illness or infectionPhysiological state
This is an acute-phase reactant — it moves substantially during any infection, injury or inflammatory episode, and the change has nothing to do with your baseline.
Do this: Wait two weeks after any illness, vaccination or injury before drawing or interpreting.
Affects: hs-CRP (High-Sensitivity C-Reactive Protein)- Recent hard trainingPhysiological state
Muscle damage and the inflammatory response to hard exercise shift this for days afterwards.
Do this: No hard or unfamiliar training for 48–72 hours before the draw.
Affects: hs-CRP (High-Sensitivity C-Reactive Protein)- Statins, NSAIDs, corticosteroidsDrug or supplement
All lower CRP, so a treated value understates the underlying inflammatory state.
Do this: Note what you were taking. Avoid NSAIDs for a few days if the question is baseline inflammation.
Affects: hs-CRP (High-Sensitivity C-Reactive Protein)- Biological variabilityPhysiological state
hs-CRP varies substantially in the same person week to week. A single value is a poor baseline.
Do this: Take two readings a fortnight apart and use the lower, or the average.
Affects: hs-CRP (High-Sensitivity C-Reactive Protein)
How to read it
What the results can and cannot tell you, with sources
Low B12 with high MMA is real deficiency and treatable — fix it and reassess cognition in three months. A raised pTau-217 should be taken to a neurologist, not to the internet. A normal result in someone worried about family history is meaningfully reassuring.
What this panel can and cannot settle
What this panel can settle, and by what logic
Nine markers doing two unrelated jobs: two of them estimate Alzheimer pathology and risk, and seven of them look for the reversible conditions that imitate it.
- pTau-217 (AD-Detect) is the strongest blood marker of Alzheimer pathology that exists. Plasma phospho-tau217 separated neuropathologically confirmed Alzheimer disease from other neurodegenerative disorders with an area under the curve of 0.89, reached 0.96 for clinical Alzheimer dementia, and distinguished abnormal from normal tau-PET scans at 0.93 Palmqvist 2020. Those are diagnostic-grade numbers in the populations studied.
- APOE Genotyping genotype is risk stratification, and one genotype is more than that. In carriers of two copies of e4, abnormal amyloid in cerebrospinal fluid was near-universal by age 65 and 75% had a positive amyloid scan — enough for the authors to argue e4 homozygosity is a distinct genetic form of the disease rather than a risk factor Fortea 2024.
- The other seven are the reversible list, and they are why the panel is worth buying at any age. Vitamin B12 with Methylmalonic Acid (MMA) finds functional deficiency behind a normal-looking number Harrington 2024; Homocysteine is a modifiable risk factor for brain atrophy Smith 2010; TSH (Thyroid-Stimulating Hormone), HbA1c (Hemoglobin A1c), Vitamin D (25-Hydroxy) and hs-CRP (High-Sensitivity C-Reactive Protein) cover thyroid, glycemic and inflammatory contributors.
What it cannot settle, and what would
A biomarker is not a diagnosis, and this is the distinction the whole panel turns on. Dementia is a clinical syndrome defined by impairment in daily function; pTau-217 (AD-Detect) measures Alzheimer pathology. Those come apart in both directions — pathology is present in cognitively normal people for a decade or more before symptoms, and plenty of impairment has nothing to do with amyloid or tau. The accuracy figures above were established in specialist cohorts against a reference standard Palmqvist 2020, and a positive result in a well 45-year-old buying it out of pocket is a different situation with a different predictive value.
APOE Genotyping tells you what is more likely, never what will happen. Most e4 carriers do not develop Alzheimer dementia and most people who do are not e4 homozygotes Fortea 2024. The result cannot be changed, cannot be treated, and once known cannot be unknown — which is a real consideration for insurance disclosure and for the people you would have to tell.
It cannot identify a non-Alzheimer dementia. Vascular cognitive impairment, dementia with Lewy bodies, frontotemporal dementia and normal-pressure hydrocephalus are diagnosed on history, examination and MRI. A normal pTau-217 (AD-Detect) in a person who is deteriorating means the cause is one of those, not that nothing is wrong.
And it cannot test your memory. Whether cognition has objectively declined is settled by neuropsychological assessment against normative data, ideally repeated. That is the measurement this panel is bought as a substitute for, and it is not one.
Draw conditions that decide whether the money is wasted
Four conditions. The first two protect specific markers; the third protects the whole panel.
- Stop B12 and B-complex supplements 1 week before. Serum Vitamin B12 follows recent intake, so a supplemented sample reports your tablet rather than your status; Methylmalonic Acid (MMA) is the marker that resists this Harrington 2024. On a panel bought to exclude a reversible cause, hiding the reversible cause is the worst possible failure.
- Plasma markers are handling-sensitive: get the sample spun and frozen promptly. Delay to centrifugation and storage temperature measurably shift biomarker concentrations Abraham 2019, and pTau-217 (AD-Detect) is the most expensive assay in the panel to have degraded by a courier.
- Not during or shortly after an acute illness. Infection raises hs-CRP (High-Sensitivity C-Reactive Protein), and acute illness with confusion is a delirium workup rather than a dementia one — a different test on a different day.
- 72 hours off biotin for the TSH (Thyroid-Stimulating Hormone), since thyroid disease is one of the reversible causes and biotin is the commonest way to get the thyroid result wrong Li 2020. Use one laboratory for Vitamin D (25-Hydroxy) as well Wise 2021.
How you would know it answered your question, and what each pattern means next
Five results, and the honest interval for each. Note that two of these should never be repeated at all.
- pTau-217 (AD-Detect) abnormal: this goes to a memory clinic, not to another blood test. Confirmation is clinical assessment with imaging and usually a cerebrospinal-fluid or PET measure Palmqvist 2020. Repeating the plasma marker in 6 months answers nothing.
- APOE Genotyping e4/e4: never repeat — the genotype is fixed. What changes with it is how hard the modifiable risks are worth treating: blood pressure, ApoB (Apolipoprotein B), HbA1c (Hemoglobin A1c), hearing, activity and sleep Fortea 2024.
- Homocysteine above 10 µmol/L with low-normal B12 or folate: treat and retest at 12 weeks. The trial evidence for slowing atrophy applies to people with raised homocysteine, which is precisely why measuring it first matters Smith 2010.
- Vitamin B12 low-normal with a raised Methylmalonic Acid (MMA): replace, then recheck MMA at 4 weeks Harrington 2024. Cognitive change from B12 repletion, where it happens at all, takes months longer than the biochemistry.
- Everything normal and the symptom is progressing: the reversible list is excluded, and the next step is a clinician with access to imaging and formal cognitive testing.
Sources read for these sections
- Palmqvist S, et al. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA 2020 · PMID 32722745
- Fortea J, et al. APOE4 homozygozity represents a distinct genetic form of Alzheimer's disease. Nature Medicine 2024 · PMID 38710950
- Smith AD, et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS One 2010 · PMID 20838622
- Harrington DJ. The application and interpretation of laboratory biomarkers for the evaluation of vitamin B12 status. Annals of Clinical Biochemistry 2024 · PMID 39367523
- Chen Z, et al. Interpretation of HbA1c lies at the intersection of analytical methodology, clinical biochemistry and hematology (Review). Experimental and Therapeutic Medicine 2022 · PMID 36382101
- Wise SA, et al. Vitamin D Standardization Program (VDSP) intralaboratory study for the assessment of 25-hydroxyvitamin D assay variability and bias. Journal of Steroid Biochemistry and Molecular Biology 2021 · PMID 34010687
- Abraham RA, et al. Effect of temperature and time delay in centrifugation on stability of select biomarkers of nutrition and non-communicable diseases in blood samples. Biochemia Medica 2019 · PMID 31223262
- Li D, Ferguson A, Cervinski MA, Lynch KL, Kyle PB. AACC Guidance Document on Biotin Interference in Laboratory Tests. J Appl Lab Med 2020 · PMID 32445355
Patterns, and where the results go
3 patterns, goals and what moves these markers
Patterns these markers can make
- High homocysteine with 'normal' B12
Homocysteine >12 · B12 in the low-normal range · Possibly MTHFR variant
Serum B12 is an insensitive marker — you can be functionally deficient at the low end of 'normal.' Homocysteine and MMA reveal what B12 alone hides.
Methylfolate + methylcobalamin + P5P, add TMG/betaine. Test MTHFR to guide which forms to use. Check for metformin or PPI use as the cause.
- B12 deficiency that a normal B12 was hiding
MMA elevated · B12 normal · Homocysteine high · Numbness, brain fog, fatigue
MMA rises when B12 is short at the tissue level regardless of what the serum number says. This is the test that settles the argument, and neurological damage from prolonged deficiency is not always reversible.
Treat it, do not re-argue the serum number. Methylcobalamin or hydroxocobalamin; injections if absorption is the problem. Look for the cause: metformin, PPIs, gastric surgery, celiac, pernicious anemia, plant-based diet.
- APOE ε4 with a normal pTau-217
APOE ε4 carrier · pTau-217 normal · no symptoms
Genuinely reassuring, and worth stating because the genotype alone frightens people. ε4 raises lifetime risk; a normal pTau-217 says the amyloid pathology those risk figures describe is not currently detectable. Many ε4 carriers never develop dementia.
Put the effort into the fourteen modifiable risk factors — hearing, blood pressure, glucose, exercise, sleep, alcohol, social connection. They account for far more than the genotype does, and unlike it they respond.
Goals this panel helps decide
In the library: what moves these markers
Questions people ask
6 answered
- What blood tests are in the Cognitive Decline & Alzheimer's Risk panel?
- 9 markers: pTau-217 (AD-Detect), APOE Genotyping, Vitamin B12, Methylmalonic Acid (MMA), Homocysteine, TSH (Thyroid-Stimulating Hormone), Vitamin D (25-Hydroxy), HbA1c (Hemoglobin A1c), hs-CRP (C-Reactive Protein, High Sensitivity).
- How much does the Cognitive Decline & Alzheimer's Risk panel cost?
- $675.95 before the discount, $608.36 with code CAMERON, which the order button applies automatically. Marek's checkout adds its one-time blood-draw fee to individual tests and shows the total before you pay.
- Do I need a doctor's order for these tests?
- No. These are ordered direct-to-consumer through Marek Diagnostics: you order online, walk into a Quest location, and results are emailed to you. No physician visit or insurance required. Not available in NY, NJ or RI.
- Does the Cognitive Decline & Alzheimer's Risk panel diagnose anything?
- No. A panel measures; it does not diagnose. It tells you which numbers are worth a conversation with a clinician and which explanations the results make more or less likely. Compare every value against the range printed on your own report.
- When should I get the Cognitive Decline & Alzheimer's Risk panel drawn?
- Fast 9–12 hours, morning. Off B12 supplements 1 week if you want a true B12 reading.
- How do I read the Cognitive Decline & Alzheimer's Risk panel results?
- Low B12 with high MMA is real deficiency and treatable — fix it and reassess cognition in three months. A raised pTau-217 should be taken to a neurologist, not to the internet. A normal result in someone worried about family history is meaningfully reassuring.
The Cognitive Decline & Alzheimer’s Risk protocol is a lesson in Skool
This page tells you what the panel measures and how to prepare. Skool is where your results get read and turned into a plan.
- The full Cognitive Decline & Alzheimer’s Risk protocol, step by step
- Cam’s method for reading these results: which number to act on first, and what to retest
- The monthly Protocol Audit: your protocol read against your labs (a premium upgrade)
5.0 (15 reviews)1,500+ members

Want it built around you?
Educational and research purposes only. Not medical advice and not a diagnosis; a panel is a starting point for a conversation with a clinician, not a substitute for one. Lab ranges vary by assay and laboratory: compare against the range printed on your own report. Some links are affiliate links; Cam may earn a commission at no extra cost to you. Medical disclaimer and affiliate disclosure